Name: TheragNos
Elevator Pitch: Polymer enhanced nano-particles for improved medical imaging
Faculty: Dr. Stephen Boyes, Ph. D. Assistant Professor Department of Chemistry and Geochemistry
Next Steps: Participate in Boulder Innovation Center Facilitated Meeting Exploring Different Commercialization Strategies for the Technology
To Indicate an Interest or for More Information: Gary Galusha, GaryG@BoulderInnovationCenter.com, 303.444.2111

Please Click Here for a PDF of the Executive Summary

Background
The incredible potential of nanomedicines to revolutionize the healthcare sector was recently highlighted by the U.S. National Science Foundation, who predicted a combined market for nano-enabled medicine (drug delivery, treatment, and diagnostics) in the U.S. by the year of 2010 of approximately $10 billion. Specifically, the targeted medical device market is expected to reach nearly $14 billion by the year 2014. Targeted therapeutics incorporate diagnostic imaging and have a much greater efficacy than the currently available technologies by overcoming many of the inherent side effects caused by these treatments.

TheragNos will provide a range of theragnostic devices incorporating a targeted diagnostic imaging component with a potential treatment capacity. A range of different surfaces, including both gold and gadolinium nanostructures, can be modified with their patent-pending technology providing a number of advantages over currently employed clinical techniques:

Molecularly targeted diagnostic imaging (MRI and CT)

Increased retention time, decreased dosage, and lessened side effect

Treatment tailored to the patients genetic profile

Gd nanoparticles have proven to be advantageous due to their increased retention times, along with exhibiting higher relaxivities than Gd chelates. Due to their increased size in comparison to the clinically employed chelates, Gd nanoparticles provide increased in vivo circulation time and also contain higher concentrations of Gd3+ per contrast agent, which when targeted yield superior MRI relaxivities

TheragNos, an early stage biotechnology company headquartered in Golden, CO, is focusing on the next generation of personalized nanomedicine products. Using our proprietary nanoparticle surface modification technique, TheragNos will make available a range of nanodevices, which focus on targeted diagnostic imaging of advanced disease.
To Indicate an Interest or for More Information: Gary Galusha, GaryG@BoulderInnovationCenter.com, 303 444 2111